The goal of the Specimen Resources and Pathology Core (SPRC) is to provide superior technical expertise to the investigators on this proposal. Experienced head and neck pathologists and cytopathologists will work closely with each SPORE project as well as the Biostatistics and Administrative Cores to ensure efficient and highly-coordinated procurement, archiving, and storage of human tissue samples. Continuous communication between the clinicians, scientists, research nurses, biostatisticians, and pathologists together with established standardized operating procedures for all core activities will provide optimal tissue collection and accurate processing, analysis, and storage of each sample. The SRPC will function as the main repository of patient specimens and will oversee specimen processing and histopathology. This Core will utilize and expand the already well-established tissue banking efforts at Emory University for translational research. Histopathologic analysis by the Core pathologists will confirm the quality and presence of the expected study tissue in research specimens. Selected cellular biomarkers will be explored using immunohistochemistry. These immunostains will be interpreted by core pathologists. Cytology specimens will be generated, and cytopathologic support in processing and interpreting the specimens will be provided. In addition, animal study specimen processing, histopathology, immunohistochemistry, and pathologic interpretive support will be provided. Taken together, the primary objectives of the Specimen Resources and Pathology Core are to: 1) Facilitate the acquisition, preservation, analysis, and dispersal of clinical samples 2) Provide accurate histopathological and cytological characterization of head and neck tissues for all project investigators, thus providing uniform quality assurance 3) Identify oral dyplasia biopsy specimens in the Oral, Head and Neck Biopsy service 4) Offer reliable centralized laboratory services to the SPORE investigators with respect to tissue samples that include histochemistry, immunohistochemical staining, in-situ hybridization, and laser capture microdissection By assisting the researchers in these translational projects, we hope to advance the understanding of how oral cancer develops and aid in the development of treatment and preventive stategies for oral cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA128613-03
Application #
7923237
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$304,248
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Wang, Xu; Beitler, Jonathan J; Huang, Wen et al. (2018) Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. Clin Cancer Res 24:858-869
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Pike, Robert; Lu, Guolan; Wang, Dongsheng et al. (2016) A Minimum Spanning Forest-Based Method for Noninvasive Cancer Detection With Hyperspectral Imaging. IEEE Trans Biomed Eng 63:653-63
Majumdar, Debatosh; Rahman, Mohammad Aminur; Chen, Zhuo Georgia et al. (2016) Anticancer activity of drug conjugates in head and neck cancer cells. Front Biosci (Elite Ed) 8:358-69
Oh, Y-T; Deng, J; Yue, P et al. (2016) Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. Oncogene 35:459-67
Pentz, Rebecca D; Hendershot, Kristopher A; Wall, Louisa et al. (2015) Development and testing of a tool to assess patient preferences for phase I clinical trial participation. Psychooncology 24:835-8
Brodie, Seth A; Li, Ge; Harvey, Donald et al. (2015) Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. Oncotarget 6:30773-86
Liu, Deli; Xiong, Huan; Ellis, Angela E et al. (2015) Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level. PLoS Genet 11:e1005277

Showing the most recent 10 out of 136 publications